As the DOJ and SEC look into two of its senior employees, Cassava Sciences’ CEO and one senior vice president have departed ...

The last few months have been difficult for Gilead, with several late-stage failures and development discontinuations. Amid ...

Novartis’ second-quarter earnings, announced Thursday, show strong performance of its blockbuster drugs, prompting the ...

This is the third episode of Denatured's discussion on diversity, equity and inclusion. Here, our guests discuss imperatives ...

BioSpace will review your content, and upon approval will post your release. In order to keep our content relevant to the life sciences industry, not all press release submissions will be approved. 1) ...

Learn five ways to answer difficult interview questions so you can leave the best impression possible on your potential ...

Agenus revealed Thursday that the FDA has “advised against” applying for accelerated approval for its investigational ...

Fresh off its $13-billion acquisition of medical devices developer Shockwave Medical, Johnson & Johnson is expecting greater ...

Roche’s oral GLP-1 receptor agonist CT-996—obtained in the $2.7 billion acquisition of Carmot Therapeutics—reduced body ...

After nixing a twice-daily version of its oral GLP-1 agonist, Pfizer is hoping to break into the weight-loss space with a ...

Mid-stage data for 4D Molecular Therapeutics’ wet AMD drug 4D-150 show improvements in visual acuity, reduced injection rate ...

As the yearslong litigation over ownership of CRISPR gene editing continues, investors have forged ahead with funding the ...